AN2 Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs to treat chronic infectious diseases, including nontuberculous mycobacterial lung disease, using its boron chemistry platform.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Readnour Robin ShaneInsider | Sell | $4K | 585at $6.02 | Sep 9, 2026 |
| Readnour Robin ShaneInsider | Sell | $3K | 523at $6.02 | Sep 9, 2026 |
| Readnour Robin ShaneInsider | Sell | $32K | 5,294at $6.02 | Sep 8, 2026 |
| Readnour Robin ShaneInsider | Sell | $28K | 4,725at $6.02 | Sep 8, 2026 |
| Readnour Robin ShaneInsider | Sell | $20K | 3,223at $6.07 | Sep 3, 2026 |
| Readnour Robin ShaneInsider | Sell | $17K | 2,877at $6.07 | Sep 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ANTX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.